BUSINESS
Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
A new 21-valent pneumococcal conjugate vaccine, Capvaxive, could help prevent severe pneumococcal infections by covering serotypes associated with high fatality and drug resistance, according to pulmonologist Hiroshi Mukae of Nagasaki University. Speaking at an MSD-hosted seminar on November 21, Mukae…
To read the full story
Related Article
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





